<DOC>
	<DOCNO>NCT02607956</DOCNO>
	<brief_summary>This study evaluate efficacy fix dose combination ( FDC ) contain bictegravir/emtricitabine/tenofovir alafenamide ( B/F/TAF ) versus dolutegravir ( DTG ) + FDC contain emtricitabine/tenofovir alafenamide ( F/TAF ) HIV-1 infect , antiretroviral treatment-naive adult Week 48 .</brief_summary>
	<brief_title>Safety Efficacy Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide HIV-1 Infected , Antiretroviral Treatment-Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Key Antiretroviral treatment naive ( ≤ 10 day prior therapy antiretroviral agent follow diagnosis HIV1 infection ) except use PrEP ( preexposure prophylaxis ) PEP ( postexposure prophylaxis ) , one month prior screen Plasma HIV 1 RNA level ≥ 500 copies/mL screen Adequate renal function : Estimated glomerular filtration rate ≥ 30 mL/min ( ≥ 0.50 mL/sec ) accord Cockcroft Gault formula Key An opportunistic illness indicative stage 3 HIV diagnose within 30 day prior screen Decompensated cirrhosis ( eg , ascites , encephalopathy , variceal bleeding ) Current alcohol substance use judge Investigator potentially interfere subject study compliance Females pregnant ( confirm positive serum pregnancy test ) Females breastfeed Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HIV</keyword>
</DOC>